Not Signed In - Initiation Of Phase III Program Using Emisphere's Eligen(R) Technology For Oral Salmon Calcitonin
Wed, 28 Feb 2007 08:00 AM EST
... Emisphere Technologies, Inc. ("Emisphere") (Nasdaq: EMIS) announced today that Novartis Pharma AG and its development partner Nordic Bioscience have notified Emisphere of the initiation of a Phase III clinical trial for the treatment of osteoporosis with an oral form of salmon calcitonin (referred to as SMC021), a new drug candidate, using Emisphere's eligen(R) delivery technology. [click link for full article] ...
Related Topics
- Assistive Technology
- Calcitonin Salmon Injection
- Antithrombin III
- Calcitonin Salmon Nasal Spray
- Information Systems
- Familial Dysautonomia
- Calcitonin
- Oral Cancer
- Assisted Reproductive Technology
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Oral Health
- Congenital antithrombin III deficiency
- Cranial mononeuropathy III - diabetic type
- Cranial mononeuropathy III - compression type
- Amoxicillin Oral Suspension
- Antithrombin
- Zidovudine Oral Syrup
- Magnetic Resonance Imaging
- Information Technology at the CDC
email this page
print this page
bookmark this page
feedback on this page
